Clinical trial
Synthetic Human Secretin in Children With Autism and Gastrointestinal…
NCT00036231 · Repligen Corporation, Industry · Terminated
Key facts
| NCT number | NCT00036231 |
|---|---|
| Title | Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction |
| Official title | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Efficacy, Safety and Tolerability of RG1068 (Synthetic Human Secretin) in Children With Autism and Gastrointestinal Dysfunction |
| Lead sponsor | Repligen Corporation, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Autism |
| Intervention type | Drug |
| Interventions | RG1068 (Synthetic Human Secretin) |
| Start date | Apr 1, 2002 |
| First posted | May 9, 2002 |
| Last update posted | Nov 21, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: